These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32866439)

  • 1. IASLC 2020 World Conference on Lung Cancer.
    Venkatesan P
    Lancet Respir Med; 2020 Oct; 8(10):e76. PubMed ID: 32866439
    [No Abstract]   [Full Text] [Related]  

  • 2. Arginine deprivation for ASS1-deficient mesothelioma.
    Burki TK
    Lancet Oncol; 2016 Oct; 17(10):e423. PubMed ID: 27622996
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
    Addeo A; Buffoni L; Di Maio M
    JAMA Oncol; 2017 Sep; 3(9):1170-1171. PubMed ID: 28114625
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
    Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
    Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multi-target tumor therapy].
    Krankenpfl J; 2005; 43(1-3):38-9. PubMed ID: 15912831
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series.
    Nief CA; No HJ; Louie CY; Vitzthum L; Das M
    Clin Lung Cancer; 2023 Jan; 24(1):76-81. PubMed ID: 36323592
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
    Jassem J; Biernat W; Bryl M; Chorostowska-Wynimko J; Dziadziuszko R; Krawczyk P; Kordek R; Kowalski DM; Krzakowski M; Olszewski W; Orłowski T; Ramlau R; Rzyman W
    Pneumonol Alergol Pol; 2014; 82(2):133-49. PubMed ID: 24615197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
    Buikhuisen WA; Qayyum F; Armato SG; Baas P
    Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
    Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
    J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
    [No Abstract]   [Full Text] [Related]  

  • 17. Pleural mesothelioma: tackling a deadly cancer.
    The Lancet Respiratory Medicine
    Lancet Respir Med; 2019 Feb; 7(2):99. PubMed ID: 30660508
    [No Abstract]   [Full Text] [Related]  

  • 18. Tazemetostat Shows Antitumor Activity in Malignant Pleural Mesothelioma.
    Cancer Discov; 2022 Jul; 12(7):1610. PubMed ID: 35621347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
    Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Principal developments in thoracic surgery].
    Grunenwald D
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S28-30. PubMed ID: 12538931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.